Aim: The aim of this study is to: (a) develop and evaluate a model to predict severe pain during wound care procedures (WCPs) so that high-risk patients can be targeted for specialized dressings and preventive pain control; and (b) identify biological factors associated with severe pain during WCPs so that novel pain control strategies can be developed.
| Background
Despite guidelines for administering preventive analgesics (World Union of Wound Healing Societies ' Initiative, 2004 ' Initiative, , 2007 Wounds UK, 2004) , current practice sometimes involves performing WCPs without analgesia or chasing pain with opioids after the procedure has started when pain is severe (Stotts et al., 2004) . When given, opioids are sometimes administered repeatedly or at doses resulting in prolonged, problematic, postprocedure sedation. Opioids can also delay healing (Martin et al., 2010; Rook, Hasan, & McCarson, 2009 ).
In addition to analgesics, current practice guidelines recommend advanced wound dressings, such as foam, hydrofibres and alginate, but provide no guidance on which patients should be targeted for these advanced wound dressing materials (World Union of Wound Healing Societies ' Initiative, 2004 ' Initiative, , 2007 Wounds UK, 2004) . As a result, clinicians may not consider advanced wound dressings based on the dressings' ability to minimize wound pain (Vermeulen, Ubbink, de Zwart, Goossens, & de Vos, 2007) .
Finally, organisations responsible for setting practice guidelines recognize the need to develop innovative pain control strategies that target specific mechanisms given the potential for adverse effects of analgesics, (World Union of Wound Healing Societies ' Initiative, 2007) . Therefore, the mechanisms that lead to severe pain during WCPs need to be identified and targeted for novel pain control interventions.
| THE STUDY

| Aims
Aim 1 of this study is to develop and evaluate a clinical risk model to predict severe pain during WCPs so that high-risk patients can be targeted for specialized dressings and preventive pain control.
Aim 2 of this study is to identify biological factors associated with severe pain during WCPs so that novel pain control strategies can be developed.
| Design/Methodology
| Design
This is a cross-sectional study which began in December 2015. The research team performs a one-time study dressing change (i.e., WCP) on enrolled participants and collects data to measure all study variables. Figure 1 depicts the study variables included for Aims 1 and 2. The development of the conceptual model of the study has been published (Gardner, Abbott, Fiala, & Rakel, 2017) .
| Setting and sample
Participants are recruited from the inpatient units at large academic hospital in the Midwest using a customized report listing all hospital inpatients with wounds, generated through EPIC© (Epic Systems Corporation, Verona, WI), the electronic medical record. Table 1 lists inclusion and exclusion criteria. Only nonburn, nondiabetic foot, fullthickness wounds are included. Burn wounds are not included because the pain associated with burn wounds is substantially different than other types of wounds and people with diabetic foot ulcers often have significant neuropathy that alters the perception of pain in both the foot and the ulcer. Only open, full-thickness wounds are included because our interest is in the pain associated with packing and dressing wounds, which is not a component of care for wounds healing by primary intention. The sample includes only adults as wound care for children and adolescents are often performed in the operating room at UIHC.
Of those patients that meet inclusion criteria, those that are non-English speaking or with a moderate to severe cognitive impairment are excluded because English and cognition abilities are essential to complete self-report tools in the study protocol (i.e., Generalized Anxiety Disorder-7 ; Patient Health Questionnaire-8 [PHQ-8]; and Pain Catastrophizing Scale). Similarly, those with sensory impairment (e.g., spinal cord injuries, nerve blocks, or other conditions resulting in lack of sensation) at the wound site are excluded because of their potential influence on pain at the wound site during the study dressing change; the primary outcome for both Aims. Wounds covered with 100% nonviable tissue (slough or eschar) are excluded because slough/eschar precludes the ability to collect wound specimens for bioburden and cytokine analyses.
Wounds with a fistula are excluded because fistulous drainage may change the composition of wound specimens collected for bioburden and cytokine analyses. Malignant wounds are excluded because the pain associated with malignant wounds is substantially different than for other types of open wounds. Finally, wounds that require debridement during the study dressing change are excluded because debridement may cause higher levels of pain independent of the dressing change procedures.
| Target enrolment
Target enrolment (consent) is 525 participants over 3½ years. Based on our data, we expect a 15% attrition rate leaving 445 participants with complete study data. Previous data suggest 36% of inpatients at UIHC have severe pain (≥8/10) with WCPs (Gardner et al., 2014) so we expect 160-445 participants to have severe pain during the
Why this study is needed?
This study has the potential to make significant contribu- 
| Methodology
| Study variables
Primary outcome variable
Pain intensity during the study dressing change is defined as the maximum pain intensity experienced during the dressing change, inclusive of removal, cleansing, specimen collection and redressing. The vertical 0-10 Numeric Rating Scale (NRS) with 0.5 increments is used to assess pain experienced in the wound during the study dressing change. The NRS pain scale is used in clinical practice, has established validity (correlation with the Visual Analogue Scale r = 0.847, p < 0.001) (Paice & Cohen, 1997) and reliability (test-retest r = 0.93) (Jensen, 2003) for assessing acute pain and is associated with higher compliance and lower failure rates than the Visual Analogue Scales (Herr, Spratt, Mobily, & Richardson, 2004) . For exploratory analyses, we are also assessing the quality of pain during the dressing change using the Short Form McGill Pain Questionnaire (SF-MPQ) (Melzack, 1987) . This study will use the 15 pain quality descriptors from the SF-MPQ. The 15 items on the SF-MPQ have established validity (r = 0.77-0.88) when compared with the Long Form McGill Pain Questionnaire (Dudgeon, Raubertas, & Rosenthal, 1993) ; and reliability (within patient correlation = 0.88-0.96 between sensory, affective and average pain scores) (Grafton, Foster, & Wright, 2005) .
Aim 1 study variables (see Table 2 for a listing and brief explanation of the variables for Aim 1). The variables for this aim are based on the literature, described in an article by Gardner et al. (2017) .
Patient factors
Patient factors associated with high pain include younger age (Stotts et al., 2004) , female sex (Morin, Lund, Villarroel, Clokie, & Feine, 2000) , African-American race (Stotts et al., 2004; White, Asher, Lai, & Burton, 1999) , high anxiety (Woo, Sadavoy, Sidani, Maunder, & Sibbald, 2008) , depressed mood, pain catastrophizing (Baker, 2003) , high levels of anticipatory pain (Woo et al., 2008) , chronic pain condition(s), and opioid tolerance (Gardner et al., 2017) . [Osman et al., 2000; Sullivan, Bishop, & Pivik, 1995] ). Table 3 summarizes the measurement tools for Anxiety, Depression, Pain
Catastrophizing, and Anticipatory Pain; and their validity and reliability. cations that differ in potency yet which are supposed to provide the same amount of pain relief (Gordon et al., 1999) .
Chronic pain conditions
Wound factors
Wound factors believed to be associated with high levels of pain during WCPs include shorter duration of injury (Meaume, Teot, Lazareth, Martini, & Bohbot, 2004) , chronic wounds (Price et al., 2008) , clinical inflammation (Gardner et al., 2014) , and high levels of resting wound pain (Gardner et al., 2017) . Clinical inflammation is defined as the presence of erythema extending 2 cm from the wound edge and heat, defined as a positive temperature gradient at the wound margin compared with a control , 2016) . The wound perimeter is "outlined" using the thermometric probe and the highest detected temperature displayed is recorded. This is repeated at a control site that is either at a contralateral location or on another site distant from the wound where the tissue appears normal (e.g., no erythema, wound, scaring). Two measures of inflammation, which is a cluster of physiological responses (i.e., heat, erythema, pain, and oedema), to increase the validity of the presence of clinical inflammation, because these signs and symptoms are subtle and have low reliability when assessed individually, are used (Doughty & McNichol, 2015) .
Duration of injury
Resting wound pain intensity is measured using a vertical 0-10 NRS with 0.5 increments as described under "pain during study dressing changes" above. The validity and reliability of the NRS was described in that section. The participant is asked how much pain they are having in their wound when resting quietly.
Aim 2 study variables (see Table 4 for a listing and brief explanation of the variables for Aim 2).
Biological mechanisms
Several biological variables represent mechanisms linked to nociceptive sensitivity during WCPs (Brennan, 2002; Sluka, Deacon, Stibal, Strissel, & Terpstra, 1999; Sluka, Vance, & Lisi, 2005 Anticipatory Pain Intensity NRS Self-report on vertical 0-10 Numeric Rating Scale with 0.5 increments. The participant is asked how much pain they expect to have during the dressing change.
The NRS was not developed to assess Anticipatory Pain, thus there is no validity or reliability data for this indication. However, Woo et al. (2008 ) & Woo (2015 used the 11-point NRS (0-10) to assess anticipatory pain associated with dressing change procedures, and found the NRS is the best method for accurately and reliably determining the participant's real-time pain experience and expectations. *The 0-10 NRS has been assessed for Reliability and Validity for Pain Intensity, this information can be found with the "Pain Intensity" variable.
Wound bioburden is measured by assessing three dimensions of bioburden: microbial load, microbial diversity, and relative abundance of potential pathogens. These dimensions are measured using swab specimens for high-throughput sequence analysis of the 16S rRNA gene yielding total microbial load, a variety of diversity metrics and the relative abundance of all microbes.
Wound specimens for the 16S rRNA analysis are obtained using Levine's technique, which has established validity compared with wound tissue specimens (Gardner et al., 2006) . A pipeline for recovering, amplifying, and sequencing bacterial 16S rRNA genes from wound swab specimens has been optimized ( Figure 2 ). DNA is isolated from samples to maximize both Gram-positive and Gram-negative bacterial and fungal recovery, as described in Grice et al. (2010) . Broad-range PCR primers, with barcodes unique for each sample, will amplify hypervariable regions 1-3 (V1-V3) of the bacterial 16S rRNA gene and sequenced on the Illumina MiSeq instrument (Caporaso et al., 2012) .
Sequences are processed in QIIME (Caporaso et al., 2010; Kuczynski et al., 2011) , prior to downstream analyses. Briefly, sequences are first clustered into OTUs (operational taxonomic units, a proxy for "species") using UCLUST (Edgar, 2010) at 97% sequence similarity.
Microbial load is measured using quantitative real-time PCR.
Microbial load is extrapolated from real-time PCR data normalized to a well-characterized standard (i.e., E. coli); this allows estimation of 16S gene copy number and the number of bacterial cells.
Microbial diversity is calculated using the following alpha diversity indices: (a) Shannon diversity index, an ecological measure of diversity that incorporates the total number of different OTUs and the relative proportion of those OTUs; (b) faith's phylogenetic distance (PD), a measure of biodiversity that incorporates phylogenetic differences between species; and (c) number of observed OTUs.
Beta-diversity, or "shared" diversity, is calculated using the UniFrac metric in forms both weighted and unweighted for relative abundance to identify association of microbial community structure with variables (e.g., level of pain). Taxonomic classification of sequences is made using BLAST, as implemented in QIIME (Caporaso et al., 2010) .
Relative abundance of putative pathogens in the wounds (e.g., S.
aureus and anaerobes) is calculated along with other bacterial taxa present, which allow us to identify additional, unrecognized putative pathogens among the wound microbiota.
Using these measures of bioburden, we found that wound dura- Wound pH is defined as the numeric value of acidity or alkalinity on a scale of 6.5-13.0, measured in increments of 0.5 using Micro Essentials, Hydrion pH paper, which was quality tested by the manufacturer using NIST traceable standards. Validity and reliability of using litmus paper for measuring pH of wound fluid has not been reported in the literature. Shukla, Shukla, Tiwary, Agrawal, and Rastogi (2007) used litmus paper to assess pH of standard solutions of known pH and confirmed accuracy of the litmus strips.
Control variables
Dressing and analgesic-intake variables (see Table 5 for a listing and brief explanation of these variables. As previously noted, these variables will be used as additional covariates for estimating the Aim 1 risk model and as covariates when assessing associations in Aim 2). Analgesic intake Preventive analgesic intake includes oral, intravenous, or topical analgesics (opioids and non-opioids) given within 1 hr of study dressing change. Procedural analgesic intake includes those opioids and nonopioids given after the start of the study dressing change until it is completed. The type, route, and dose (mg or lg) of opioid and nonopioid analgesics taken or administered to the participant are recorded. This information is then used to convert opioids to morphine equivalents in milligrams using established conversion factors (Dowell et al., 2016 ) and nonopioids to number taken/dose. Equianalgesic calculation provides a point of reference when comparing two medications that differ in potency yet which are supposed to provide the same amount of pain relief (Gordon et al., 1999 ).
Type of dressings
| Data collection protocol
For consented participants, a team of at least two research members, one who is a CWON and one Registered Nurse (RN) research assistant (RA), complete the study dressing and collect study data/ specimens. Using the same CWON to change the dressing, controls variability in dressing change technique that could have an impact on pain intensity.
Prior to the study dressing change the participant's medical record is reviewed by the RA for demographic information, medical history, opioid medication history for the previous 5 days and up until 1 hr prior to the dressing change, and adjuvant analgesic medication history. This information is verified with the participant before the dressing change. If the participant has any pain medications available, the team works with the participant's nurse to have them administered as ordered before the study dressing change.
The RA then administers or assists the participants with the GAD-7, PHQ-8, and PCS surveys. After survey completion, the RA asks the participant to rate their resting and anticipatory pain. For Aim 1, clinically accessible wound and patient factors will be combined in a logistic regression model to produce a risk scale that predicts probability of severe pain during WCPs based on a patient's levels of wound and patient factors. The ability of this model to distinguish between severe and not-severe pain will be assessed by the area under the ROC curve (AUC), which estimates the probability of correctly discriminating between a patient with severe pain and one without severe pain. For Aim 2, we will assess the ability of each biological mechanism to individually predict severe versus not-severe pain during WCPs, as measured by the AUC. Additionally, a "best" model for predicting severe versus not-severe pain will be determined using forward stepwise logistic regression, where all the biological mechanisms will be candidate predictors. The usefulness of this model will also be described by the AUC. Dressing factors and analgesic intake that may alter pain during WCPs are being measured and will be included as covariates in the Aim 1 logistic regression model and as control variables in the Aim 2 analysis. AUC estimated for the Aim 1 and Aim 2 multiple logistic regression models will be adjusted downward, using bootstrap validation methods as described by Harrell (2015) , to account for overly optimistic AUC estimates due to estimating the regression model coefficients and AUC from the same data set (both aims), as well to account for performing variable selection (Aim 2) using the same data set.
| Ethical considerations
The appropriate Institutional Review Board (IRB) has approved all study protocols. The IRB approves all protocol modifications in addition to an annual continuing review to ensure compliance with human participant protections.
Briefly, the research team verbally describes all study procedures to eligible patients and their right to withdraw from the study at any time, the right to refuse to answer survey questions, and that their decision to participate or not will not have an impact on their care. Participants are then provided a written consent form to sign. All participants who complete the study are reimbursed for their time.
| Validity and reliability/rigour
The validity and reliability of all study measures are reported under Design/Methodology. We will also analyse and report the validity of the established survey tools (e.g., GAD-7, PHQ-8) in our population.
The reliability of study data will be analysed through the use of consistency checks to identify inaccurate data and or recording.
Although this is not a randomized clinical trial, we are using a CON-SORT framework to describe recruitment and enrolment data according to inclusion/exclusion criteria and withdrawal from the study. Therefore, we will be able to fully describe the participants and nonparticipants in the study that may influence or bias study findings.
| DISCUSSION
Based on experience, adjustments were made in this application that facilitate obtaining an adequate sample, including a 3-year plan for enrolment. If we encounter difficulty obtaining the needed numbers of participants, or if enrolment of chronic wounds falls below 30%
of the sample, we will seek to case-find, recruit, enrol, and collect data from outpatient UIHC clinics, including the vascular clinic.
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| 1971
Type of wound may have an interaction effect on pain during WCPs. Alternative strategies will be used to examine separately wound and patient factors for acute versus chronic wounds.
The proposed study addresses "severe" pain (8-10 on a 10-point NRS) because, in our view, predicting and controlling this level of pain would be a significant advance in wound care. We do recognize that moderate levels of pain (4-7) are also problematic so predictions of moderate pain will be examined in exploratory analyses and biological mechanisms associated with moderate pain will be explored by alternative analyses that treat pain during WCP as an interval level variable.
The use of 16S rRNA gene sequencing to characterize wound bioburden may fail to identify significant relationships between bioburden and pain during WCPs. An alternative strategy will be to employ much more expensive and difficult metagenomic techniques that provide a much higher resolution of microbial characteristics, such as strain and pathogenicity factors.
| Limitations
The cross-sectional study design precludes examining the role of pain during WCPs on wound outcomes, such as healing. A second limitation is recruitment of inpatients only, which may limit generalisation of study findings to outpatients.
| CONCLUSION
Although previous studies have examined various aspects of pain during WCPs, the major innovation of this proposal over previous studies is that it is the first to systematically examine a comprehensive set of wound, patient, and biological factors for their individual and collective associations with pain during WCPs using precisely defined and rigorously measured study variables. This study has the potential to make significant contributions because the predictive risk model developed in Aim 1 will enable clinicians to target those patients requiring preventive pain control, thereby (a) eliminating the spiralling impact of painful procedures on nociceptor sensitisation and development of anticipatory pain, (b) increasing appropriate use of advanced wound dressings to minimize painful dressing changes, and (c) reducing the use of opioids and their undesirable side effects. This study will provide valuable information to begin development of a clinical tool to guide healthcare provider's management of wound pain during painful dressing changes. In addition, this study will provide information on mechanisms associated with severe pain during WCPs so novel pain control strategies can be developed. substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; drafting the article or revising it critically for important intellectual content.
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